Greetings, all!
Another IPM despatch for your delight and delectation as the summer holiday season approaches.
Policy loves an instrument that can be announced: a global fund, a price-transparency rule, a biotechnology package, a compulsory licence, a tariff or an artificial-intelligence framework. Each can move a headline. None, by itself, moves a patient through a health system.
This Brief follows that gap from data to delivery. A genetic score can be precise yet unreliable for populations missing from its training data. A market can price the prospects of a clinical trial without producing evidence. Global finance can buy equipment without creating local capacity, just as a posted price can expose a charge without making care understandable or affordable.
Europe can announce a biotech strategy without connecting discovery to trials, manufacturing and reimbursement. A licence can alter legal access without producing a medicine; a tariff can alter trade without securing supply. Even a powerful cancer-prevention discovery can remain unused if it never becomes a routine clinical conversation.
These are not arguments against ambition. They are arguments for implementation. Across every story, the test is the same: does the policy create a durable route to earlier diagnosis, appropriate testing, timely treatment and better outcomes?
The shortcut is not the pathway.
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
Personalised Risk – But Only For Some?
Polygenic risk scores could identify people at increased risk of cardiovascular disease, breast cancer and diabetes years before symptoms appear. But prediction is only as reliable as the data behind it.
Genomic research has been dominated by people of European ancestry. One analysis found that 67% of early polygenic-score studies included only European-ancestry participants; when those scores were applied to people of African ancestry, median predictive performance fell to 42% of that achieved in European populations. (Nature)
Breast cancer shows both the risk and the remedy. A European-derived 313-variant score performed poorly among women of African ancestry. Researchers then assembled data from more than 40,000 African-ancestry women, identified 12 susceptibility regions and produced a better-performing score. (PubMed; Nature Genetics)
Diversity also creates discoveries for everyone. Rare PCSK9 variants identified in Black participants were associated with an 88% reduction in coronary heart disease and helped establish a therapeutic target now used internationally. (PubMed)
Better modelling can improve portability, but algorithms cannot recreate genetic information that was never collected. Scores need population-specific validation, transparent performance reporting and evidence that they improve outcomes beyond conventional clinical risk factors.
Personalised medicine cannot be built from one part of humanity and exported uncritically to everyone else. That distinction between prediction and evidence becomes sharper still when clinical evidence itself becomes something to bet on.
Clinical Trials are not Casinos
Prediction markets are entering drug development. Kalshi has launched contracts on FDA decisions and plans wagers on whether clinical trials meet their primary endpoints, arguing that financially backed forecasts can cut through industry hype. (Kalshi News)
But a market price is not scientific evidence, and a trial is not an ordinary event. Trials depend on controlled information, independent oversight and the trust of patients who accept uncertainty to advance medical knowledge. Good Clinical Practice requires participant protection and reliable results. (ICH)
Investigators, monitors, contractors, sites and regulators may each hold fragments of confidential information. The risks are greater in biomarker-defined trials, where small populations and specialised centres mean an enrolment delay, safety event or protocol amendment could move a thin market sharply, and perhaps reveal information about a handful of participants.
FDA approval is also not a binary scientific verdict. It integrates efficacy, safety, manufacturing quality, companion diagnostics and the proposed population. Compressing that judgement into a wager creates an illusion of certainty.
Trading on active trials should therefore be prohibited until results are public, with health-related contracts scrutinised by financial, medicines and research-ethics authorities. Patients enter trials to advance medicine, not to generate a gambling event.
Markets may aggregate opinion, but they cannot replace research governance. The same warning applies when financial instruments are expected to perform the work of health systems.
A Global Fund Cannot Substitute for a Health System
The World Inequality Lab has proposed global taxation, large-scale redistribution and a Global Justice Fund investing heavily in health, education and climate action. The diagnosis is persuasive. The prescription is less certain.
The healthcare problem is not simply raising more money; it is converting investment into lasting capacity. Medical oxygen provides a warning. Fewer than half of facilities in low- and middle-income countries have uninterrupted access because the pathway also requires production, distribution, electricity, technical expertise, maintenance and regulation. (World Health Organization)
More sustainable models build ownership from the outset. Gavi requires countries to co-finance vaccines and increase their contributions as their capacity grows. Rwanda’s Butaro Cancer Center combined external finance with national protocols, referral pathways, pathology, procurement, records and workforce training. (Gavi; Partners In Health)
For personalised medicine, financing a molecular-diagnostics pilot without trained staff, quality assurance, maintenance, data systems, referral routes and reimbursement creates a demonstration, not a service. The economic case matters too: the World Bank estimates that every US$1 invested in strong primary healthcare in East Asia and the Pacific can generate up to US$16 in economic benefits. (World Bank)
Global finance can be catalytic, but it should be judged by domestic capability, measurable returns and a route to local ownership. Money must be connected to delivery. Information must likewise be connected to action, which is where price transparency often falls short.
A Price Tag is not a Patient Pathway
US lawmakers are again trying to bring healthcare prices out of the shadows. The Patients Deserve Price Tags Act would require providers to publish cash prices, while broader proposals would disclose negotiated rates, rebates and patient cost-sharing. (US Senate)
The principle is sound: patients should know what care will cost before the bill arrives. But publishing a price does not create an understandable or competitive market. More than 500 hospitals reportedly received compliance warnings in 2026, despite federal transparency requirements dating from 2021. (CMS)
Accuracy is also weak. One comparison found that posted insurance prices matched bills exactly or closely in only 20.5% of cases. A price that bears little relation to the eventual charge is another layer of confusion. (The Washington Post)
Nor can cancer patients shop for pathology, molecular testing, imaging, surgery and medicines as isolated products. The cheapest item may not produce the best—or least expensive, overall pathway. Transparency can strengthen insurer-provider negotiations: one study found reductions of 5.1% for surgery and 9.1% for radiology. Yet estimated system-wide reductions remain only 0.1–1%. (PubMed)
Prices must be accurate, comparable and connected to quality, outcomes and personalised out-of-pocket estimates. The same distinction between announcement and operation sits at the heart of Europe’s biotechnology ambitions.
The Race to Make Europe a Power Biotech House
Europe has a rare opportunity to strengthen its position in global biotechnology, but it should not confuse opportunity with leadership. Uncertainty in American research and regulation may redirect scientists and capital, yet Europe needs a compelling pathway of its own: trusted institutions, predictable rules and patient capital.
Other regions show what this requires. Australia’s R&D Tax Incentive reduces the risk of long-term research and has helped attract clinical trials and early development. China is aligning scientific capability, clinical infrastructure, capital and industrial strategy, while international companies increasingly license Chinese-developed assets.
Europe is responding. BioTechEU is expected to mobilise up to €10 billion during 2026–2027, and the proposed EU Biotech Act aims to improve trial coordination, regulation and scale-up. But capital announcements and legislation are only components.
Europe must connect discovery, multinational trials, growth finance, manufacturing, regulatory assessment, reimbursement and procurement. Otherwise, European laboratories will continue producing science that is financed, developed and commercialised elsewhere.
The final measure is patient access: earlier diagnosis, appropriate biomarker testing and timely treatment, not simply patents, companies or capital raised. Europe’s biotech race will be won by the region that builds the full pathway.
And if Europe succeeds in generating innovation, the next question is whether health systems can afford it. That is where compulsory licensing enters the debate.
A Licence Can Change the Price. Can It Change Access?
Compulsory licensing is often portrayed as an emergency measure used by poorer countries. That description is outdated. A global review recorded 149 occasions between 2001 and 2024 when licences were issued, proposed or requested; 61% were executed, and high-income countries accounted for 54% of cases during the past decade. (BMJ Global Health)
The cases show both leverage and limitation. Colombia used action on dolutegravir to open access to cheaper HIV treatment, while Germany protected the supply of raltegravir during a patent dispute. Cystic-fibrosis modulators present a sharper personalised-medicine test: only around 12% of eligible patients worldwide have access to triple therapy. Six licensing campaigns were recorded between 2019 and 2024, and two helped secure discounts without a licence being issued. (BMJ Global Health)
But Canada’s attempt to export generic HIV medicines to Rwanda took nearly four years and remains the only completed export under the WTO’s special mechanism. A licence does not provide manufacturing knowledge, regulatory approval, diagnostics, supply chains or trained professionals. (World Trade Organization)
Compulsory licensing is therefore neither an attack on innovation nor a complete access strategy. It is a legitimate negotiating and procurement backstop when monopoly pricing or supply restrictions conflict with public health.
A licence can open the legal door; the health system must still take the patient through it. Legal access also means little without physical supply, the weakness exposed from the opposite direction by the tariff debate.
Reshoring Medicines Requires More Than a Tariff
The United States plans to keep imported generics tariff-free for two years from August 2026, then impose tariffs of 100%, rising to 200% a year later. The objective is domestic production. The risk is that medicines disappear before factories arrive. (Reuters)
Generics account for more than 90% of US prescriptions but less than 13% of drug spending. Their low prices depend on narrow margins; a government analysis found that 70% of newly launched generic injectables were still unprofitable after three years. (FDA)
The fragility is already visible. In 2023, a plant closure contributed to cisplatin and carboplatin shortages: 93% of surveyed cancer centres reported shortages of carboplatin, 70% lacked cisplatin and 16% delayed treatment. Hurricane Helene then damaged a North Carolina facility in 2024, creating widespread shortages of intravenous fluids. Domestic concentration can merely relocate the single point of failure. (US Government Accountability Office)
Civica Rx offers a more credible model: long-term purchasing agreements, stable prices, multiple suppliers and reserve inventory. It supplies more than 70 medicines to over 1,400 hospitals and is building substantial sterile-injectable capacity. (Civica Rx)
Resilience requires sustainable prices, guaranteed volumes, quality incentives, diversified supply and regulatory support. The test is not where a medicine is labelled; it is whether it is affordable and on the shelf when treatment is due.
Not every missed pathway begins with a shortage, however. Sometimes the evidence and opportunity are already present, but the clinical conversation never happens.
The August Watch
August is for holidays. September is for new ideas.
While you enjoy a well-deserved break, whether by the sea or in the mountains, you can already plan what’s next. Registrations are now open for our events in New York (September 24), Stockholm (September 12) and Dublin (October 2).
Visit our Events page to explore what’s coming up and reserve your place.
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.
International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium
This email was sent to jayasinghtec29@gmail.com. You are receiving this email because you are part of the IPM Alliance network or have engaged with our activities, briefings, events, or policy work.
